Company release, 20 March 2024 at 5:00 p.m. (EET)

The Board of Directors of Nightingale Health Plc (“Nightingale Health”) has in its meeting on 18 December 2023, approved request of shareholders to convert 79,765 EMP shares to Series B shares in accordance with Article 5 in the Articles of Association.

As a result of conversion of shares, the number of the Nightingale Health’s Series A shares is 20,585,924 and Series B shares is 39,233,735 and EMP shares is 1,098,800. The conversion does not affect the total amount of shares which is 60,918,459. The number of votes of Nightingale Health’s shares is after the conversion 245,092,975.

The conversions of shares were registered in the Trade Register on 20 March 2024. The converted shares will be listed on the Nasdaq Helsinki Ltd together with the old shares as of 21 March 2024.

For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com

Certified Adviser:
Oaklins Merasco Ltd. tel. +358 9 6129 670

About Nightingale Health
Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com